Back to top
more

TransMedics Group (TMDX)

(Real Time Quote from BATS)

$86.06 USD

86.06
979,041

+0.56 (0.66%)

Updated Nov 8, 2024 03:39 PM ET

After-Market: $86.01 -0.05 (-0.06%) 4:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Will TransMedics (TMDX) Gain on Rising Earnings Estimates?

by Zacks Equity Research

TransMedics (TMDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Illumina (ILMN) Q1 Earnings Beat, Adjusted Operating Loss Widens

by Zacks Equity Research

Illumina (ILMN) surpasses expectations in the first quarter in a challenging global macroeconomic environment.

Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View

by Zacks Equity Research

Tandem Diabetes (TNDM) outperforms in the first quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.

TransMedics Group, Inc. (TMDX) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

TransMedics (TMDX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Is TransMedics (TMDX) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in TransMedics (TMDX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

TransMedics (TMDX) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

TransMedics (TMDX) delivered earnings and revenue surprises of 800% and 16.24%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Riya Anand headshot

How You Should Play Hologic (HOLX) Ahead of Q2 Earnings

by Riya Anand

Hologic's (HOLX) second-quarter 2024 earnings will likely reflect gains from the GYN surgical business and the growing adoption of Panther instruments.

Edwards Lifesciences (EW) Q1 Earnings Top, 2024 Sales View Up

by Zacks Equity Research

Strong performance of SAPIEN 3 Ultra RESILIA platform and sustainable TAVR growth drives Edwards Lifesciences (EW) Q1 revenues.

Moumi Mondal headshot

Should Lifeward (LFWD) be in Your Portfolio Ahead of Q1 Earnings?

by Moumi Mondal

Lifeward's (LFWD) first-quarter 2024 results are expected to reflect the benefits of several milestone achievements from last year.

Exploring Analyst Estimates for TransMedics (TMDX) Q1 Earnings, Beyond Revenue and EPS

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for TransMedics (TMDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

ResMed (RMD) Q3 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

ResMed's (RMD) fiscal 2024 third-quarter performance reflects another strong period of execution across the entire business, resulting in impressive top and bottom-line growth.

Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View

by Zacks Equity Research

Labcorp (LH) sets a strong foundation for the year ahead with its impressive performance in the first quarter of 2024.

TransMedics (TMDX) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

In the latest trading session, TransMedics (TMDX) closed at $88.88, marking a -1.9% move from the previous day.

Charles River (CRL) to Report Q1 Earnings: Here's What to Expect

by Zacks Equity Research

Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.

LivaNova (LIVN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insulet (PODD) Awaits Q1 Earnings Release: Here's What to Expect

by Zacks Equity Research

Strong global new customer starts fueled by the ongoing Omnipod 5 demand are expected to significantly benefit Insulet's (PODD) first-quarter performance.

How Should You Play Centene (CNC) Ahead of Q1 Earnings?

by Zacks Equity Research

Centene's (CNC) first-quarter earnings are likely to reflect significant growth in commercial marketplace membership.

TransMedics (TMDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should You Buy HCA Healthcare (HCA) Ahead of Q1 Earnings?

by Zacks Equity Research

HCA Healthcare's (HCA) first-quarter results are likely to reflect increased admissions and patient days.

TransMedics (TMDX) Increases Yet Falls Behind Market: What Investors Need to Know

by Zacks Equity Research

In the closing of the recent trading day, TransMedics (TMDX) stood at $84.74, denoting a +0.69% change from the preceding trading day.

Should You Buy STERIS (STE) Stock Ahead of Q4 Earnings?

by Zacks Equity Research

STERIS (STE) is expected to have witnessed the normalization of the Healthcare backlog, as the company is currently able to ship at a faster pace than the receipt of new orders.

Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings?

by Zacks Equity Research

Exact Sciences' (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth, offset slightly by increasing operating costs.

Henry Schein (HSIC) Gears Up for Q1 Earnings: Factors to Note

by Zacks Equity Research

Henry Schein's (HSIC) first-quarter 2024 results are likely to indicate a strong sales recovery post last year's cybersecurity incident.

What's in the Cards for Zimmer Biomet (ZBH) in Q1 Earnings?

by Zacks Equity Research

Within the Hips business, Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery, banking on strategic product launches in the first quarter.